Purple Biotech announced that the CEO, Gil Efron, has been hospitalized following an accident and will be on medical leave that is expected to last several months while he undergoes rehabilitation to recover from his injuries. The Company’s Board of Directors has appointed Isaac Israel, a current Board member and the former CEO, to serve as acting CEO during Gil Efron’s absence. Purple Biotech will continue to execute its 2023 business plan as expected, with no anticipated changes in its corporate progress and clinical programs
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PPBT:
- Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron
- Purple Biotech reports biomarker data from CM24 Phase 1 dose escalation study
- Purple Biotech announces first patient dosed in Phase 2 trial of CM24
- Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial
- Purple Biotech reports Q4 EPS (33c) vs (29c) last year